JP7755772B2 - 化合物又はその塩及びその製造方法、組成物、過酸化水素除去剤、並びに、細胞毒性抑制剤 - Google Patents

化合物又はその塩及びその製造方法、組成物、過酸化水素除去剤、並びに、細胞毒性抑制剤

Info

Publication number
JP7755772B2
JP7755772B2 JP2025519185A JP2025519185A JP7755772B2 JP 7755772 B2 JP7755772 B2 JP 7755772B2 JP 2025519185 A JP2025519185 A JP 2025519185A JP 2025519185 A JP2025519185 A JP 2025519185A JP 7755772 B2 JP7755772 B2 JP 7755772B2
Authority
JP
Japan
Prior art keywords
mass
less
compound
hydrogen peroxide
cytotoxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025519185A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024257775A5 (https=
JPWO2024257775A1 (https=
Inventor
淳 松本
邦男 小坂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagase and Co Ltd
Original Assignee
Nagase and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagase and Co Ltd filed Critical Nagase and Co Ltd
Publication of JPWO2024257775A1 publication Critical patent/JPWO2024257775A1/ja
Publication of JPWO2024257775A5 publication Critical patent/JPWO2024257775A5/ja
Application granted granted Critical
Publication of JP7755772B2 publication Critical patent/JP7755772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2025519185A 2023-06-15 2024-06-12 化合物又はその塩及びその製造方法、組成物、過酸化水素除去剤、並びに、細胞毒性抑制剤 Active JP7755772B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023098209 2023-06-15
JP2023098209 2023-06-15
PCT/JP2024/021265 WO2024257775A1 (ja) 2023-06-15 2024-06-12 化合物又はその塩及びその製造方法、組成物、過酸化水素除去剤、並びに、細胞毒性抑制剤

Publications (3)

Publication Number Publication Date
JPWO2024257775A1 JPWO2024257775A1 (https=) 2024-12-19
JPWO2024257775A5 JPWO2024257775A5 (https=) 2025-06-12
JP7755772B2 true JP7755772B2 (ja) 2025-10-16

Family

ID=93852144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025519185A Active JP7755772B2 (ja) 2023-06-15 2024-06-12 化合物又はその塩及びその製造方法、組成物、過酸化水素除去剤、並びに、細胞毒性抑制剤

Country Status (5)

Country Link
EP (1) EP4729511A1 (https=)
JP (1) JP7755772B2 (https=)
KR (1) KR20260022421A (https=)
CN (1) CN121311472A (https=)
WO (1) WO2024257775A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007300916A (ja) 2006-04-10 2007-11-22 Manabu Nukina エルゴチオネインの製造方法
CN109091422A (zh) 2018-08-01 2018-12-28 上海应用技术大学 含榆黄菇提取液的化妆品及其制备方法
CN109293572A (zh) 2018-09-26 2019-02-01 上海市农业科学院 一种提取榆黄菇中麦角硫因与多糖的方法
WO2021177397A1 (ja) 2020-03-04 2021-09-10 長瀬産業株式会社 Ｌ－エルゴチオネイン含有組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008156320A (ja) 2006-12-26 2008-07-10 Hydrox Kk 抗酸化性機能水
JP2020103100A (ja) 2018-12-27 2020-07-09 小林製薬株式会社 細胞内の抗酸化機能亢進剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007300916A (ja) 2006-04-10 2007-11-22 Manabu Nukina エルゴチオネインの製造方法
CN109091422A (zh) 2018-08-01 2018-12-28 上海应用技术大学 含榆黄菇提取液的化妆品及其制备方法
CN109293572A (zh) 2018-09-26 2019-02-01 上海市农业科学院 一种提取榆黄菇中麦角硫因与多糖的方法
WO2021177397A1 (ja) 2020-03-04 2021-09-10 長瀬産業株式会社 Ｌ－エルゴチオネイン含有組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SERVILLO, L. et al.，An uncommon redox behavior sheds light on the cellular antioxidant properties of ergothioneine，Free Radical Biology & Medicine，2015年，79，pp. 228-236，DOI: 10.1016/j.freeradbiomed.2014.11.017

Also Published As

Publication number Publication date
WO2024257775A1 (ja) 2024-12-19
EP4729511A1 (en) 2026-04-22
JPWO2024257775A1 (https=) 2024-12-19
KR20260022421A (ko) 2026-02-19
CN121311472A (zh) 2026-01-09

Similar Documents

Publication Publication Date Title
Zhang et al. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
US8143069B2 (en) Fluorescent probe and method of measuring hypochlorite ion
EP3380457B1 (en) Monosulfonic phenyltetrazole compounds with applications
JP7450559B2 (ja) 疾患の処置のためのｋｄｍ１ａ阻害剤
ES2605564T3 (es) Sal farmacéuticamente aceptable de (E)-N-[4-[[3-cloro-4-(2-piridilmetoxi)fenil]amino]-3-ciano-7-etoxi-6-quinolil]-3-[(2R)-1-metilpirrolidin-2-il]prop-2-enamida, método de preparación para la misma, y uso médico de la misma
NO20071521L (no) Nye fenylaminopyrimidin derivater som hemmere av BCR-ABL kinase
JP7359439B2 (ja) ニコチンアミドｎ－メチルトランスフェラーゼ（ｎｎｍｔ）のキノリン由来小分子阻害剤及びその使用
ATE457981T1 (de) 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung
KR101282833B1 (ko) 신규한 히스톤 디아세틸라제 저해제로서의 치환된프로페닐피페라진 유도체
EP4172159A1 (en) Compositions and methods for modulating hair growth
DE602004005960D1 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
WO2017017048A1 (en) Analogs of adamantylureas as soluble epoxide hydrolase inhibitors
Adhikari et al. Colorimetric and fluorescence probe for the detection of nano-molar lysine in aqueous medium
Missbach et al. Substituted 5, 7-diphenyl-pyrrolo [2, 3d] pyrimidines: potent inhibitors of the tyrosine kinase c-Src
JP7755772B2 (ja) 化合物又はその塩及びその製造方法、組成物、過酸化水素除去剤、並びに、細胞毒性抑制剤
MA29943B1 (fr) Derives de pyrazolo[4,3-d] pyrimidine-5-yle utilises comme inhibiteurs de pde5
MXPA06000986A (es) Compuestos.
Ino et al. Characterization of inhibitor binding sites of mitochondrial complex I using fluorescent inhibitor
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
Fantacuzzi et al. Screening of NOS activity and selectivity of newly synthesized acetamidines using RP-HPLC
CR20250409A (es) Derivados de oxazolo[4,5-b]pirazina y oxazolo[4,5-b]piridina como inhibidores de nlpr3 para el tratamiento de, por ejemplo, enfermedades inflamatoria
Detremmerie et al. Endothelium-dependent contractions of isolated arteries to thymoquinone require biased activity of soluble guanylyl cyclase with subsequent cyclic IMP production
EP1553409A1 (en) Reagents for the measurement of peroxynitrites
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren
MX2024012970A (es) Inhibidores de la 17-beta-hidroxiesteroide deshidrogenasa tipo 13 que contienen pirimidinona

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250402

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251003

R150 Certificate of patent or registration of utility model

Ref document number: 7755772

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150